Johnson & Johnson (NYSE:JNJ) Hits New 1-Year Low at $151.23

Shares of Johnson & Johnson (NYSE:JNJ – Get Rating) reached a new 52-week low on Thursday . The stock traded as low as $151.23 and last traded at $152.09, with a volume of 942035 shares. The stock had previously closed at $152.57.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Atlantic Securities upped their price target on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Credit Suisse Group assumed coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $174.73.

Johnson & Johnson Stock Performance

The company has a market capitalization of $401.11 billion, a P/E ratio of 22.85, a P/E/G ratio of 2.63 and a beta of 0.54. The business has a 50-day moving average of $166.90 and a 200-day moving average of $168.79. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. During the same period last year, the company earned $2.13 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.93%. Johnson & Johnson’s payout ratio is 67.06%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geller Advisors LLC increased its stake in shares of Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after buying an additional 648 shares during the period. Simon Quick Advisors LLC increased its stake in shares of Johnson & Johnson by 296.9% during the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after buying an additional 6,537 shares during the period. Lokken Investment Group LLC increased its stake in shares of Johnson & Johnson by 1.6% during the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after buying an additional 201 shares during the period. Keebeck Alpha LP increased its stake in shares of Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after buying an additional 525 shares during the period. Finally, Lincoln Capital Corp increased its stake in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.